{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:47:35Z","timestamp":1782427655767,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-026-00321-4","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:02:41Z","timestamp":1782424961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling"],"prefix":"10.1186","volume":"12","author":[{"given":"Gaetano","family":"Santulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26\u201336.","journal-title":"N Engl J Med"},{"key":"321_CR2","doi-asserted-by":"crossref","unstructured":"Bazhan N, Jakovleva T, Feofanova N, Denisova E, Dubinina A, Sitnikova N, Makarova E. Sex differences in liver, adipose tissue, and muscle transcriptional response to fasting and refeeding in mice. Cells. 2019;8.","DOI":"10.3390\/cells8121529"},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","volume":"15","author":"MP Cooreman","year":"2024","unstructured":"Cooreman MP, Butler J, Giugliano RP, Zannad F, Dzen L, Huot-Marchand P, Baudin M, Beard DR, Junien JL, Broqua P, et al. The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis. Nat Commun. 2024;15:3962.","journal-title":"Nat Commun"},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/13543784.2023.2206560","volume":"32","author":"SA Doggrell","year":"2023","unstructured":"Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023;32:355\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021;385:1547\u201358.","journal-title":"N Engl J Med"},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K, Investigators S-. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4161\/adip.24075","volume":"2","author":"E Fuente-Martin","year":"2013","unstructured":"Fuente-Martin E, Argente-Arizon, Ros P, Argente J, Chowen JA. Sex differences in adipose tissue: It is not only a question of quantity and distribution. Adipocyte. 2013;2:128\u201334.","journal-title":"Adipocyte"},{"key":"321_CR8","doi-asserted-by":"crossref","unstructured":"Harris E. Triple-hormone combination retatrutide induces 24% body weight loss. JAMA. 2023;330:306.","DOI":"10.1001\/jama.2023.12055"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389:514\u201326.","journal-title":"N Engl J Med"},{"key":"321_CR10","doi-asserted-by":"crossref","unstructured":"Kamata S, Honda A, Ishikawa R, Akahane M, Fujita A, Kaneko C, Miyawaki S, Habu Y, Shiiyama Y, Uchii K, et al. Functional and structural insights into the human PPARalpha\/delta\/gamma targeting preferences of anti-NASH investigational drugs, Lanifibranor, Seladelpar, and Elafibranor. Antioxidants (Basel). 2023;12.","DOI":"10.3390\/antiox12081523"},{"key":"321_CR11","doi-asserted-by":"crossref","unstructured":"Kansakar U, Jankauskas SS, Pande S, Mone P, Varzideh F, Santulli G. Orforglipron: a comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. Int J Mol Sci. 2026:27.","DOI":"10.3390\/ijms27031409"},{"key":"321_CR12","doi-asserted-by":"publisher","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","volume":"149","author":"P Karakasis","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023;149:155710.","journal-title":"Metabolism"},{"key":"321_CR13","doi-asserted-by":"crossref","unstructured":"Liskiewicz D, Novikoff A, Khalil A, Akindehin S, Campbell JE, Candela P, Castelino RL, Coupland C, Culot M, Dodson WS, et al. GLP-1R-GIPR-PPARalpha\/gamma\/delta quintuple agonism corrects obesity and diabetes in mice. Nature. 2026.","DOI":"10.1038\/s41586-026-10619-z"},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s42255-022-00617-6","volume":"4","author":"C Quarta","year":"2022","unstructured":"Quarta C, Stemmer K, Novikoff A, Yang B, Klingelhuber F, Harger A, Bakhti M, Bastidas-Ponce A, Bauge E, Campbell JE, et al. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice. Nat Metab. 2022;4:1071\u201383.","journal-title":"Nat Metab"},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402:529\u201344.","journal-title":"Lancet"},{"key":"321_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2023.23141","volume":"331","author":"K Ruder","year":"2024","unstructured":"Ruder K. At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide. JAMA. 2024;331:9\u201311.","journal-title":"JAMA"},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jhep.2025.03.003","volume":"82","author":"S Sabatini","year":"2025","unstructured":"Sabatini S, Gastaldelli A. Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor. J Hepatol. 2025;82:950\u20132.","journal-title":"J Hepatol"},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037\u201348.","journal-title":"Nat Med"},{"key":"321_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","volume":"27","author":"AR Saxena","year":"2021","unstructured":"Saxena AR, Gorman DN, Esquejo RM, Bergman A, Chidsey K, Buckeridge C, Griffith DA, Kim AM. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2021;27:1079\u201387.","journal-title":"Nat Med"},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"eadp5765","DOI":"10.1126\/scitranslmed.adp5765","volume":"16","author":"KW Sloop","year":"2024","unstructured":"Sloop KW, Cox AL, Wainscott DB, White A, Droz BA, Stutsman C, Showalter AD, Suter TM, Dunbar JD, Snider BM, et al. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024;16:eadp5765.","journal-title":"Sci Transl Med"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389:877\u201388.","journal-title":"N Engl J Med"},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","volume":"24","author":"S Wharton","year":"2025","unstructured":"Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025;24:240.","journal-title":"Cardiovasc Diabetol"},{"key":"321_CR24","doi-asserted-by":"crossref","unstructured":"Yoon M. PPARalpha in obesity: sex difference and estrogen involvement. Res 2010. PPAR. 2010.","DOI":"10.1155\/2010\/584296"},{"key":"321_CR25","first-page":"1251","volume":"51","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Zhang R, Wang S. Effect of Dapagliflozin Combined with Cognitive Behavior Training on Quality of Life and Cognitive Function in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Mild Cognitive Impairment. Iran J Public Health. 2022;51:1251\u20138.","journal-title":"Iran J Public Health"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00321-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00321-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:02:44Z","timestamp":1782424964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00321-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00321-4","relation":{},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Prof. Gaetano Santulli is the Editor-in-Chief of Cardiovascular Diabetology - Endocrinology Reports. The Editorial Office of the Journal assigned this manuscript to another Editor, who independently supervised the peer-review process.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}